In a large cohort study of 260 SARS-CoV-2-infected individuals with varying degrees of severity [94], visfatin levels were higher in critically ill patients with COVID-19 than in non-COVID-19 mild and severe ICU patients. This evidence concerns the gene NAMPT and COVID-19.